- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03287037
The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression
To Investigate the Effect of Transcranial Direct Current Stimulation (tDCS) on Depressive Symptoms, Neurocognitive Function and Heart Rate Variability in Unipolar Depression and Bipolar Depression
Study Overview
Status
Intervention / Treatment
Detailed Description
Background
Transcranial direct current stimulation encompasses the induction of a relatively weak constant current flow through the cerebral cortex via scalp electrodes . Dependent on stimulation polarity, this results in a modulation of cortical excitability and spontaneous neural activity. The technique was established in the 1950s and 1960s primarily in animals. In these early studies it was shown that subthreshold DC stimulation increases spontaneous neuronal activity if the anode is placed above or within the cortex, while exposure to cathodal polarity results in reduced activity. This is caused by a subthreshold membrane depolarization by anodal and a hyperpolarization by cathodal stimulation. It was demonstrated in humans that the after-effects of tDCS depend on modifications of NMDA receptor-efficacy. The after-effects of tDCS are blocked by the NMDA receptor antagonist dextromethorphan, and prolonged by the partial NMDA receptor-agonist D-cycloserine. This tDCS polarity-dependent alteration of NMDA receptor function seems to be initiated by the respective membrane potential shift and probably by the accompanying cortical activity modification,because it is prevented by the sodium channel blocker carbamazepine. Intraneuronal calcium concentration also contributes, because calcium channel antagonists eliminate the excitability-enhancing after-effects of anodal tDCS. Recently, tDCS has been reported to be a novel, non-invasive and safe therapeutic tool to treat neuropsychiatric disorders including depression. This therapeutic tool has been reported to show promising effect in treating unipolar and bipolar depression. However, the sample sizes have been small. Further work is needed to see if these early promising studies replicate. Much evidence has indicated that patients with depression show hypoactivity over left dorsolateral prefrontal cortex (DLPFC) and hyperactivity over right DLPFC. We therefore hypothesize that tDCS over DLPFC with anode placed at left DLPFC and cathode placed at right DLPFC would reduce depressive symptoms in patients with unipolar depression and bipolar depression.
The study aimed to investigate whether tDCS over DLPFC could modify depressive symptoms, neurocognitive function and heart rate variability of unipolar and bipolar depression.
Study design: open-label study.
Participants: 60 patients with unipolar depression and 60 with bipolar depression.
Others: see Arms and Interventions, Eligibility Criteria or Outcome Measures.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 114
- Tri-Service General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients who met DSM-IV-TR criteria for major depressive disorder and bipolar depression and had moderate to severe depression severity (HAM-D score more than 17) were included in the study.
Exclusion Criteria:
- pregnancy or breastfeeding.
- having epilepsy, severe physical illness, any current psychiatric comorbidity or history of substance dependence.
- having contraindications for transcranial electrical/magnetic stimulation.
- having intracranial metal foreign bodies.
- having a history of intracranial neoplasms or surgery, or a history of severe head injuries or cerebrovascular diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: tDCS over DLPFC
Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www.
neuroconn.de/dc-stimulator_plus_en/)
was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2).
The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4.
Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays.
The twice daily sessions were separated by at least 3 hours.
|
We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients.
Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www.
neuroconn.de/dc-stimulator_plus_en/)
was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2).
The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4.
Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays.
The twice daily sessions were separated by at least 3 hours.
All patients were maintained on their treatment throughout the study period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline score of Hamilton Depression Rating Scale (HAM-D) at the timepoint immediately after tDCS, at one week and one month after tDCS
Time Frame: One month
|
Depression severity
|
One month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline score of Young Mania Rating Scale (YMRS) at the timepoint immediately after tDCS, at one week and one month after tDCS
Time Frame: One month
|
Hypomania/mania severity
|
One month
|
Changes from baseline score of Hamilton Anxiety Rating Scale (HAM-A) at the timepoint immediately after tDCS, at one week and one month after tDCS
Time Frame: One month
|
Anxiety severity.
|
One month
|
Changes from basline heart rate variability (HRV) at the timepoint immediately after tDCS, at one week and one month after tDCS
Time Frame: One month
|
Index of autonomic functioning.
|
One month
|
Changes from baseline results of continuous performance test (CPT) at the timepoint immediately after tDCS, at one week and one month after tDCS
Time Frame: One month
|
Performance of prefrontal-mediated task.
|
One month
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2-103-03-002-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on tDCS over DLPFC
-
Bar-Ilan University, IsraelRecruitingTranscranial Direct Current Stimulation | Transcranial Alternating Current StimulationIsrael
-
Federal University of ParaíbaCompletedAutistic Disorders SpectrumBrazil
-
Beijing Normal UniversityCompleted
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Recruiting
-
Jakub AntczakAndrzej Frycz Modrzewski Krakow UniversityNot yet recruitingBipolar Disorder | Unipolar DepressionPoland
-
Bambino Gesù Hospital and Research InstituteRecruiting
-
Hospital de Clinicas de Porto AlegreCompletedPain | Working Memory | Transcranial Direct Current StimulationBrazil
-
Samsung Medical CenterCompletedPost-stroke Cognitive ImpairmentKorea, Republic of
-
Samsung Medical CenterCompletedMild Cognitive ImpairmentKorea, Republic of
-
University Hospital, BonnClemens Mielacher, University Hospital, BonnCompletedDepressive Disorder | Depression | Depressive Disorder, Major | Depressive EpisodeGermany